Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011189 | 1.00 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL30788435 | 0.94 | ABL1 (0.88) | ABL1 | |
| SCHEMBL30788443 | 0.94 | ABL1 (0.88) | ABL1 | |
| SCHEMBL30788449 | 0.93 | ABL1 (0.87) | ABL1BCR | |
| SCHEMBL15442784 | 0.93 | ABL1 (0.87) | ABL1BCR | |
| SCHEMBL24123159 | 0.92 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL30011770 | 0.92 | ABL1 (1.00) | ABL1 | |
| SCHEMBL24123283 | 0.92 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL30011137 | 0.92 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL30010951 | 0.92 | ABL1 (1.00) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-9722188-B2 | Material for organic electronic device, and organic electronic device using the same | LG CHEM, LTD. (KR) | 2017-08-01 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | ABL1 76/4885BCR 56/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885BCR 298/4885 |
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | ABL1, BCR, LTK | ABL1 1/4885BCR 2/4885 |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | CD4, ICOS, NFATC1 | ABL1 237/4885BCR 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.